Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase 9A (PDE9A) is a high-affinity, cGMP-specific phosphodiesterase enzyme that catalyzes the hydrolysis of cyclic nucleotides, primarily cGMP, converting them into their corresponding monophosphates. This enzymatic activity regulates intracellular concentrations of cGMP and modulates various signal transduction pathways. PDE9A is expressed in the brain, heart, and other tissues and is implicated in cognitive function and cardiac hypertrophy. It is a therapeutic target for neurological disorders like Alzheimer's disease and cardiovascular diseases.
Inhibition of PDE9A leads to increased intracellular cGMP levels.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase 9A (None).